2022
Pragmatic randomized trial assessing the impact of digital health technology on quality of life in patients with heart failure: Design, rationale and implementation
Victoria‐Castro A, Martin M, Yamamoto Y, Ahmad T, Arora T, Calderon F, Desai N, Gerber B, Lee KA, Jacoby D, Melchinger H, Nguyen A, Shaw M, Simonov M, Williams A, Weinstein J, Wilson FP. Pragmatic randomized trial assessing the impact of digital health technology on quality of life in patients with heart failure: Design, rationale and implementation. Clinical Cardiology 2022, 45: 839-849. PMID: 35822275, PMCID: PMC9346973, DOI: 10.1002/clc.23848.Peer-Reviewed Original ResearchConceptsQuality of lifeHF patientsYale New Haven Health SystemKansas City Cardiomyopathy QuestionnaireDigital health technologiesHeart failure careHealth technologiesDigital health interventionsDisease exacerbationHF clinicUsual carePrimary outcomeClinical outcomesHeart failurePatient engagementPatientsHealth interventionsDigital health toolsPatient empowermentHealth systemPatient usabilityHealth toolsEarly detectionFirst enrollmentHealthcare system
2021
AACC Guidance Document on Laboratory Investigation of Acute Kidney Injury
El-Khoury JM, Hoenig MP, Jones GRD, Lamb EJ, Parikh CR, Tolan NV, Wilson FP. AACC Guidance Document on Laboratory Investigation of Acute Kidney Injury. The Journal Of Applied Laboratory Medicine 2021, 6: 1316-1337. PMID: 33973621, DOI: 10.1093/jalm/jfab020.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsAcute kidney injuryKidney injuryNew biomarkersPotential acute kidney injuryInsulin-like growth factor binding protein 7Growth factor binding protein 7Early detectionLong-term complicationsLaboratory investigationsEmergence of biomarkersHealth care costsBinding protein 7AKI alertsKidney damageClinical indicationsCystatin CSudden episodeCare costsTissue inhibitorDiagnostic thresholdMetalloproteinases 2Test utilizationPreponderance of evidenceTraditional markersExpert recommendations